Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

@article{Packer2015AngiotensinRN,
  title={Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.},
  author={Milton Packer and John J V McMurray and Akshay S. Desai and Jianjian Gong and Martin P. Lefkowitz and Adel R. Rizkala and Jean Lucien Rouleau and Victor C. Shi and Scott Solomon and Karl Swedberg and Michael R. Zile and Karl Andersen and Juan Luis Arango and J. Malcolm O. Arnold and Jan Bělohl{\'a}vek and Michael B{\"o}hm and Sergey A. Boytsov and Lesley Jean Burgess and Walter Cabrera and Carlos Calvo and Chen-Huan Chen and Andrej Duk{\'a}t and Yan Carlos Duarte and Andrejs Ērglis and Michael Fu and Efra{\'i}n A G{\'o}mez and Angel Gonz{\`a}lez-Medina and Albert Hagege and Jun Huang and Tzvetana Katova and Songsak Kiatchoosakun and K Kim and {\"O}mer Kozan and Edmundo Bayram Llamas and Felipe Mart{\'i}nez and B{\'e}la Merkely and Iv{\'a}n Mendoza and Arend Mosterd and Marta Negrusz-Kawecka and Keijo J. Peuhkurinen and Felix Jos{\'e} Alvares Ramires and Jens Refsgaard and Arvo Rosenthal and Michele Senni and Antonio S. Sibulo and Jos{\'e} Carlos Silva-Cardoso and Iain B Squire and Randall C. Starling and John R. Teerlink and Johan Vanhaecke and Dragoş Vinereanu and Raymond Chi-Wing Wong},
  journal={Circulation},
  year={2015},
  volume={131 1},
  pages={54-61}
}
BACKGROUND Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. METHODS AND RESULTS We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a… CONTINUE READING